Skip to main content
TipRanks
Go Ultimate75% OFF

Benitec Biopharma (BNTC) AI Stock Analysis

319 Followers
BNTC

Benitec Biopharma

(NASDAQ:BNTC)

Select Model
Rating:48Neutral
Price Target:$9.00â–²(10.43% Upside)
Action:reiterated
Date:11/14/26

The score is held down primarily by weak financial performance (no revenue, sizable ongoing losses, and continued negative cash flow), with technicals also indicating a broader downtrend. Offsetting factors include a very low-debt balance sheet with meaningful cash and positive corporate events tied to encouraging BB-301 clinical results and continued regulatory progress.

Positive Factors
Low leverage and cash reservesMinimal debt materially limits creditor pressure and preserves financial flexibility while Benitec advances its pipeline. The reported cash balance provides resources to fund ongoing development, and the company retains substantial borrowing capacity if additional financing becomes necessary.
Negative Factors
No revenue and persistent lossesBenitec has not established a revenue base and remains deeply unprofitable, indicating that its value depends on successful future development rather than current operating earnings. Persistent losses also limit internal funding capacity and leave results exposed to clinical and regulatory execution.

Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%BNTC-37.98%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$284.35M
Dividend Yield
―
Average Volume (3M)
177.45K
Price to Earnings (P/E)
-7.8
Beta (1Y)
0.92
Revenue Growth
―
EPS Growth
-12.64%
Country
US
Employees
24
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Benitec Biopharma Business Overview & Revenue Model

Company Description

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines th...

Benitec Biopharma Financial Statement Overview

Summary

Development-stage profile with $0 revenue and large recurring losses (TTM net loss ~-$49.5M; EBIT ~-$55.9M) keeps fundamentals weak. Offsetting this, the balance sheet is a key strength with minimal debt (~$0.64M vs. equity ~$169.6M) and cash burn has moderated versus 2025, though operating cash flow and free cash flow remain negative (~-$17.3M TTM).

Income Statement

9Very Negative

Balance Sheet

66Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue000075.00K73.00K
Gross Profit-363.00K-481.00K-396.00K075.00K64.00K
EBITDA-53.93M-50.71M-41.37M-21.66M-18.70M-17.78M
Net Income-49.51M-45.55M-37.92M-21.75M-19.56M-18.21M
Balance Sheet
Total Assets179.10M182.62M99.59M52.21M4.46M5.97M
Cash, Cash Equivalents and Short-Term Investments176.37M179.97M97.74M50.87M2.48M4.06M
Total Debt642.00K762.00K849.00K284.00K559.00K811.00K
Total Liabilities9.45M5.61M2.30M4.96M4.26M3.09M
Stockholders Equity169.65M177.01M97.30M47.25M202.00K2.88M
Cash Flow
Free Cash Flow-17.36M-16.62M-23.61M-19.58M-18.01M-15.91M
Operating Cash Flow-17.25M-16.52M-23.59M-19.40M-18.01M-15.90M
Investing Cash Flow-106.04K-105.00K-18.00K-179.00K-1,000-13.00K
Financing Cash Flow102.83M98.98M70.48M68.03M16.02M0

Benitec Biopharma Technical Analysis

Technical Analysis SentimentNegative
Last Price8.15

Price Trends

50DMA9.59Negative
100DMA11.13Negative
200DMA11.37Negative

Market Momentum

MACD-0.10Negative
RSI43.35Neutral
STOCH27.55Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Negative. The current price of 8.15 is below the 20-day moving average (MA) of 8.91, below the 50-day MA of 9.59, and below the 200-day MA of 11.37, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 43.35 is Neutral, neither overbought nor oversold. The STOCH value of 27.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTC.

Benitec Biopharma Risk Analysis

Benitec Biopharma disclosed 67 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.A number of our stockholders hold significant amounts of our common stock and unexercised warrants to acquire common stock, and therefore could exert significant influence over us.Q2, 2024

Benitec Biopharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BNTC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PEPGPEPG59Neutral$268.73M-3.13-58.18%――62.59%
KRROKRRO55Neutral$169.10M-1.35-117.05%―-82.47%3.73%
DTILDTIL54Neutral$196.95M-5.71-58.09%―6353.01%84.80%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BNTCBNTC48Neutral$294.37M-7.82-27.60%――-12.64%
EDITEDIT47Neutral$281.67M-2.97-130.43%―7.43%74.00%
PRQRPRQR40Underperform$162.29M-2.76-70.45%―19.49%-4.53%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%BNTCPRQREDITDTILKRROPEPGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BNTC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BNTCBenitec Biopharma8.15-4.95-37.79%
PRQRProQR Therapeutics BV1.15-0.88-43.35%
EDITEditas Medicine Inc.1.82-0.70-27.58%
DTILPrecision Biosciences7.052.2346.27%
KRROKorro Bio, Inc.12.325.9192.20%
PEPGPepGen Inc.3.88-1.65-29.84%

Benitec Biopharma Corporate Events

Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements

Benitec Biopharma Reports Fiscal First-Quarter Results and Clinical Progress

Positive
Nov 13, 2026

On Nov. 13, 2026, Benitec reported first-quarter fiscal 2027 results and clinical updates for BB-301, its investigational treatment for Oculopharyngeal Muscular Dystrophy-related dysphagia. Interim results presented on Oct. 28 showed a 100% responder...

Business Operations and StrategyProduct-Related Announcements

Benitec Biopharma reports positive BB-301 trial results

Positive
Oct 28, 2026

On October 28, 2026, Benitec Biopharma reported positive interim results from its ongoing Phase 1b/2a first-in-human trial of BB-301 in patients with Oculopharyngeal Muscular Dystrophy-related dysphagia. Across both low- and high-dose cohorts, all ni...

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Benitec advances BB-301 gene therapy after FDA feedback

Positive
Oct 5, 2026

On October 5, 2026, Benitec Biopharma reported that the U.S. Food and Drug Administration provided formal feedback following a Type C meeting held in the third quarter of 2026 regarding the pivotal study of BB-301, its investigational gene therapy fo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026